PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
IPO Year: 2021
Exchange: NASDAQ
Website: procept-biorobotics.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
8/11/2023 | $42.00 | Overweight | Piper Sandler |
5/31/2023 | Outperform | William Blair | |
10/31/2022 | Neutral | BTIG Research | |
10/25/2022 | $58.00 | Buy | Truist |
9/2/2022 | $49.00 | Overweight | Wells Fargo |
7/15/2022 | $47.00 | Overweight | KeyBanc Capital Markets |
6/23/2022 | $53.00 | Buy | B. Riley Securities |
3/9/2022 | $48.00 → $42.00 | Buy | B of A Securities |
3/9/2022 | $25.00 → $30.00 | Outperform | SVB Leerink |
11/5/2021 | $46.00 → $55.00 | Outperform | SVB Leerink |
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)
8-K - PROCEPT BioRobotics Corp (0001588978) (Filer)
10-Q - PROCEPT BioRobotics Corp (0001588978) (Filer)
8-K - PROCEPT BioRobotics Corp (0001588978) (Filer)
8-K - PROCEPT BioRobotics Corp (0001588978) (Filer)
10-Q/A - PROCEPT BioRobotics Corp (0001588978) (Filer)
8-K - PROCEPT BioRobotics Corp (0001588978) (Filer)
10-Q - PROCEPT BioRobotics Corp (0001588978) (Filer)
144 - PROCEPT BioRobotics Corp (0001588978) (Subject)
8-K - PROCEPT BioRobotics Corp (0001588978) (Filer)
DEF 14A - PROCEPT BioRobotics Corp (0001588978) (Filer)
4 analysts have expressed a variety of opinions on PROCEPT BioRobotics (NASDAQ:PRCT) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 1 0 0 0 In the assessment of 12-month price targets, analysts unveil insights for PROCEPT BioRobotics, presenting an average target of $75.25, a high estimate of $79.00, and a low estimate of $72.00. Surpassing
Truist Securities analyst Richard Newitter maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and raises the price target from $72 to $79.
PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that the American Medical Association ("AMA") has established a new Current Procedural Terminology ("CPT") Category I code for transurethral waterjet resection of prostate tissue ("Aquablation therapy") to treat benign prostatic hyperplasia ("BPH"). In response to increased utilization of Aquablation therapy and strong evidence for its clinical outcomes, the AMA accepted PROCEPT BioRobotics' application for a Category I CPT code, which will replace the existing Category III CPT code starting January 1,
4 analysts have shared their evaluations of PROCEPT BioRobotics (NASDAQ:PRCT) during the recent three months, expressing a mix of bullish and bearish perspectives. In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 3 1 0 0 0 Last 30D 1 1 0 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 1 0 0 0 0 Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $70.0, with a high estimate of $75.00 and a low estimate of $58.00. Witnessing a positi
TD Cowen analyst Joshua Jennings maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and raises the price target from $65 to $75.
Piper Sandler analyst Matt O'Brien maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and raises the price target from $67 to $75.
PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced long-term, real-world data showcasing the benefits of Aquablation therapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) at both academic and commercial settings. The results were presented this past weekend at the American Urological Association (AUA) Annual Meeting in San Antonio, Texas. "The data presented at AUA confirm the safety and long-term durability of Aquablation therapy in treating men with symptomatic benign prostatic hyperplasia, regardless of prostate size or shape,"
Truist Securities analyst Richard Newitter maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Buy and raises the price target from $63 to $72.
Carl J. St. Bernard Appointed as Chief Executive Officer Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of direct surgical access to catheter-based interventions, announced today that it has exited stealth mode with a $21 million new round of financing. Sonder Capital was a key participant in the round that included participation from multiple strategic investors. The funding will be used to support the company's upcoming pivotal trial for Pulmonary Embolism and development of additional clinical applications of the Endoportal ControlTM technology. "For decades, the
Co-founders and industry luminaries Dr. Fred Moll and Jay Watkins will assume the newly created role of Co-chair as firm closes its latest fund, Futures II Sonder Capital, a leading venture capital firm focused on identifying teams and technologies that will transform healthcare, today announced the appointment of firm Co-founder Kate Garrett as Managing Partner. In this pivotal role, Garrett will spearhead Sonder's next phase of growth as the firm closes Sonder Futures II, its second early stage fund. With Garrett becoming Managing Partner, Sonder Co-founders and industry luminaries Fred Moll, M.D. and Jay Watkins will maintain their roles as partners and assume the newly created posit
LISLE, Ill., Feb. 08, 2024 (GLOBE NEWSWIRE) -- CTS Corporation (NYSE:CTS), a leading global designer and manufacturer of custom engineered solutions that "Sense, Connect and Move," today announced that Amy M. Dodrill has been appointed to its board of directors, effective February 8, 2024, and will serve as a member of the nominating, governance and sustainability and technology and transactions committees. Ms. Dodrill comes to CTS with over 25 years of experience in medical and technology companies and a proven track record of successfully leading and profitably growing global businesses serving key end markets. Ms. Dodrill most recently served as President of Baxter's Global Surgical
Neptune Medical, a leading innovator in medical technology, is pleased to announce the appointment of Dr. Fred Moll as Chairman of the Board. Dr. Moll, a seasoned entrepreneur and influential figure in the medical technology industry considered to be the father of medical robotics, brings a wealth of experience and expertise to Neptune Medical. Dr. Fred Moll is currently a Managing Partner at Sonder Capital, a venture capital firm focused on investing in breakthrough healthcare technologies. His illustrious career includes founding Intuitive Surgical, a pioneer in robotic-assisted minimally invasive surgery, and Auris Health, which was acquired by Johnson & Johnson. In addition to his r
REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the appointment of Mary Garrett to its Board of Directors. Ms. Garrett most recently served on the board of Hillrom Corporation which was acquired by Baxter International Inc. in December 2021. Ms. Garrett was the governance committee chair and served on the audit committee of Hill-Rom. She also previously served as a board member and was on the audit committee of Ethan Allen Interiors, Inc. Prior to these roles and her retirement in 2015, Ms. Garrett was the
REDWOOD CITY, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- PROCEPT® BioRobotics Corporation (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced the appointment of Elisabeth Sandoval to its Board of Directors. Ms. Sandoval currently serves as a consultant to the pharmaceutical industry and is a member of the board of directors of Intersect ENT, Inc., Satsuma Pharmaceuticals, Inc. and Vyne Therapeutics, Inc. She is also on the Board of privately held Alastin Skincare. Ms. Sandoval previously served as the Chief Commercial Officer and Executive Vice President of Corporate Strategy at Alder Biopharmaceuti
SC 13D/A - PROCEPT BioRobotics Corp (0001588978) (Subject)
SC 13D/A - PROCEPT BioRobotics Corp (0001588978) (Subject)
SC 13G - PROCEPT BioRobotics Corp (0001588978) (Subject)
SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)
SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)
SC 13G - PROCEPT BioRobotics Corp (0001588978) (Subject)
SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)
SC 13G - PROCEPT BioRobotics Corp (0001588978) (Subject)
SC 13G/A - PROCEPT BioRobotics Corp (0001588978) (Subject)
SC 13D/A - PROCEPT BioRobotics Corp (0001588978) (Subject)
SAN JOSE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced FDA 510(k) clearance of its next-generation platform, the HYDROS™ Robotic System. Leveraging insights from over 50,000 procedures, HYDROS features FirstAssist AI™ treatment planning, advanced image guidance, robotic resection, and a streamlined workflow. HYDROS is designed to improve efficiency, enhance surgeon and staff experience and deliver a more accurate and consistent treatment plan for better clinical outcomes. "We are pleased to bring the H
SAN JOSE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2024. Recent Highlights Total revenue of $53.4 million for the second quarter of 2024, an increase of 61% compared to the prior period in 2023U.S. handpiece and consumables revenue of $27.3 million for the second quarter of 2024, an increase of 101% compared to the prior period in 2023Sold 47 robotic systems in the U.S. in the second quarter of 2024U.S. system and rental revenue of $17.
SAN JOSE, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2024 after market close on Thursday, August 1, 2024. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/qsztnzfu/ Dial-in registration for sell-side research
SAN JOSE, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2024. Recent Highlights Total revenue of $44.5 million for the first quarter of 2024, an increase of 83% compared to the prior year period in 2023U.S. handpiece and consumables revenue of $23.6 million for the first quarter of 2024, an increase of 101% compared to the prior year period in 2023Sold 38 U.S. robotic systems in the first quarter of 2024U.S. system and rental revenue of
SAN JOSE, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the first quarter of 2024 after market close on Wednesday, May 1, 2024. The Company's management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/2ag2438d Dial-in registration for sell-side research an
SAN JOSE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported financial results for the year ended December 31, 2023. Recent Highlights Total revenue of approximately $43.6 million for the fourth quarter of 2023, an increase of 83% compared to the prior year periodU.S. system and rental revenue of $16.6 million for the fourth quarter of 2023, an increase of 59% compared to the prior year periodU.S. handpiece and consumables revenue of $21.6 million for the fourth quarter of 2023, an increase of 109% compared
SAN JOSE, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported preliminary unaudited revenue for the quarter and fiscal year ended December 31, 2023. Preliminary, Unaudited Revenue Highlights: Total revenue for the fourth quarter of 2023 is expected to be in the range of $43.3 million to $43.6 million, compared to $23.8 million in the prior year period. Total U.S. revenue of approximately $40.0 million to $40.3 million for the fourth quarter of 2023Total U.S. Handpieces sold of approximately 6,400 resultin
SAN JOSE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2023. Recent Highlights Total revenue of $35.1 million for the third quarter of 2023, an increase of 72% compared to the same period in 2022U.S. handpiece and consumables revenue of $17.0 million for the third quarter of 2023, an increase of 113% compared to the same period in 2022Third quarter of 2023 U.S. monthly account utilization increased sequentially by 5% compared to the se
SAN JOSE, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2023 after market close on Wednesday, November 1, 2023. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/cycnvr77 Dial-in registration for s
REDWOOD CITY, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2023. Recent Highlights Total revenue of $33.1 million for the second quarter of 2023, an increase of 98% compared to the same period in 2022Sold a record 40 U.S. robotic systems in the second quarter of 2023U.S. system and rental revenue of $14.8 million for the second quarter of 2023, an increase of 74% compared to the same period in 2022U.S. handpiece and consumables revenue of $
Piper Sandler initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $42.00
William Blair initiated coverage of PROCEPT BioRobotics with a rating of Outperform
BTIG Research initiated coverage of PROCEPT BioRobotics with a rating of Neutral
Truist initiated coverage of PROCEPT BioRobotics with a rating of Buy and set a new price target of $58.00
Wells Fargo initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $49.00
KeyBanc Capital Markets initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $47.00
B. Riley Securities initiated coverage of PROCEPT BioRobotics with a rating of Buy and set a new price target of $53.00
B of A Securities reiterated coverage of PROCEPT BioRobotics with a rating of Buy and set a new price target of $42.00 from $48.00 previously
SVB Leerink reiterated coverage of PROCEPT BioRobotics with a rating of Outperform and set a new price target of $30.00 from $25.00 previously
SVB Leerink reiterated coverage of PROCEPT BioRobotics with a rating of Outperform and set a new price target of $55.00 from $46.00 previously
SAN JOSE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Wells Fargo Healthcare Conference in Boston, Massachusetts. Management is scheduled to present on Wednesday, September 4 at 1:30 p.m. Eastern Time. A live webcast of each event, as well as an archived recording, will be available on the "Investors" section of the company's website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days aft
SAN JOSE, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced FDA 510(k) clearance of its next-generation platform, the HYDROS™ Robotic System. Leveraging insights from over 50,000 procedures, HYDROS features FirstAssist AI™ treatment planning, advanced image guidance, robotic resection, and a streamlined workflow. HYDROS is designed to improve efficiency, enhance surgeon and staff experience and deliver a more accurate and consistent treatment plan for better clinical outcomes. "We are pleased to bring the H
Carl J. St. Bernard Appointed as Chief Executive Officer Jupiter Endovascular, Inc., a medical technology startup developing a new class of endovascular procedures using Endoportal ControlTM to bring the precision and control of direct surgical access to catheter-based interventions, announced today that it has exited stealth mode with a $21 million new round of financing. Sonder Capital was a key participant in the round that included participation from multiple strategic investors. The funding will be used to support the company's upcoming pivotal trial for Pulmonary Embolism and development of additional clinical applications of the Endoportal ControlTM technology. "For decades, the
Neptune Medical, a leader in medical device innovation, today announced the successful spinout of its subsidiary, Jupiter Endovascular, following the completion of a $97 million Series D financing. Sonder Capital and Olympus Corporation of the Americas were significant participants in this round, along with investments from other existing and new investors. This financing will strengthen Neptune Medical as a gastrointestinal-focused company expanding into robotics for GI disease, as evidenced by the recent appointment of medical robotics pioneer Dr. Fred Moll as Chairman of the Board. It will also enable Jupiter Endovascular to focus on its novel endovascular technology platform. "Neptu
SAN JOSE, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended June 30, 2024. Recent Highlights Total revenue of $53.4 million for the second quarter of 2024, an increase of 61% compared to the prior period in 2023U.S. handpiece and consumables revenue of $27.3 million for the second quarter of 2024, an increase of 101% compared to the prior period in 2023Sold 47 robotic systems in the U.S. in the second quarter of 2024U.S. system and rental revenue of $17.
SAN JOSE, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the "Company") (NASDAQ:PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2024 after market close on Thursday, August 1, 2024. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by following one of the below links: Webcast link for interested listeners: https://edge.media-server.com/mmc/p/qsztnzfu/ Dial-in registration for sell-side research
SAN JOSE, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that the American Medical Association ("AMA") has established a new Current Procedural Terminology ("CPT") Category I code for transurethral waterjet resection of prostate tissue ("Aquablation therapy") to treat benign prostatic hyperplasia ("BPH"). In response to increased utilization of Aquablation therapy and strong evidence for its clinical outcomes, the AMA accepted PROCEPT BioRobotics' application for a Category I CPT code, which will repla
SAN JOSE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Truist Securities MedTech Conference in Boston, Massachusetts. Management is scheduled to present on Tuesday, June 18 at 1:20 p.m. Eastern Time. A live webcast of each event, as well as an archived recording, will be available on the "Investors" section of the company's website at: https://ir.procept-biorobotics.com. The webcasts will be archived and available for replay for at least 90 days after
SAN JOSE, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced that members of management will present at the upcoming 2024 Leerink Partners Healthcare Crossroads Conference in Austin, Texas. Management is scheduled to present on Wednesday, May 29 at 10:20 a.m. Eastern Time. Additionally, members of management will present at the upcoming 44th Annual William Blair Growth Stock Conference in Chicago. Management is scheduled to present on Tuesday, June 4 at 5:00 p.m. Eastern Time. A live webcast of each event, as well as an
SAN JOSE, Calif., May 06, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ:PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced long-term, real-world data showcasing the benefits of Aquablation therapy for the treatment of symptomatic benign prostatic hyperplasia (BPH) at both academic and commercial settings. The results were presented this past weekend at the American Urological Association (AUA) Annual Meeting in San Antonio, Texas. "The data presented at AUA confirm the safety and long-term durability of Aquablation therapy in treating men with symptomatic benign p